Morphosys AG O.N. (MORG)

15.980 +0.220 (+1.40%)
Close EUR Disclaimer

Morphosys AG O.N. Company Profile

Industry
Biotechnology
Sector
Healthcare
Employees
648
Equity Type
ORD
MorphoSys AG, a commercial-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutic antibodies for patients suffering from cancer and autoimmune diseases in the United States. It offers Tafasitamab, an antibody for the treatment of B cell malignancies, including diffuse large B-cell lymphoma, follicular lymphoma, and marginal zone lymphoma. The company also develops Pelabresib, a small molecule that is in Phase II clinical trial to treat myelofibrosis; Felzartamab, an antibody directed against CD38, which is in Phase I/II clinical trials for the treatment of anti-PLA2R-positive membranous nephropathy, an autoimmune disease; and CPI-0209, a small molecule that is in Phase I/II designed to promote anti-tumor activity by inhibiting EZH2. In addition, it develops Gantenerumab, an antibody for the treatment of Alzheimer’s diseases through its pharmaceutical partners; Otilimab, an antibody for rheumatoid arthritis; Tremfya, an antibody to treat psoriasis, psoriatic arthritis, and palmoplantar pustulosis; and MOR210/TJ210, an antibody to treat immuno-oncology and autoimmune diseases. MorphoSys AG has a regional licensing agreement with I-Mab Biopharma to develop and commercialize felzartamab in China, Taiwan, Hong Kong, and Macau; a strategic alliance with the LEO Pharma; a joint collaboration and license agreement with Incyte Corporation to develop and commercialize MorphoSys investigational compound tafasitamab; and a clinical collaboration with Incyte Corporation and Xencor, Inc. to investigate the combination of tafasitamab, plamotamab, and lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma, and relapsed or refractory follicular lymphoma. The company was founded in 1992 and is headquartered in Planegg, Germany.
Contact Information
Address
Planegg,82152 Germany
Phone
49 89 89927 0
Fax
49 89 89927 222
Top Executives
Name
Age
Since
Title
Marc Cluzel 66 2012 Independent Chairman of the Supervisory Board
Michael Brosnan 66 2018 Independent Member of the Supervisory Board
Krisja Vermeylen 59 2017 Independent Member of the Supervisory Board
George S. Golumbeski 64 2018 Independent Deputy Chairman of Supervisory Board
Sharon Curran 54 2019 Independent Member of Supervisory Board
Raymond W. Sweet 0 2016 Member of Scientific Advisory Board
Gunther R. Adolf 0 2016 Member of Scientific Advisory Board
Sergio A. Quezada 46 2016 Member of Scientific Advisory Board
Bruce D. Cheson 0 2016 Member of Scientific Advisory Board
Andrew Cheng 0 2022 Member of Supervisory Board
Clear All
0Selected
Please try another search

Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data.
Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.

Related Articles